Oncology

#Immuno-oncology #Immunotherapy #Oncology #Personalised medicine

Navigating the landscape of immunotherapy

Giusy Di Conza, Head of Research at iOnctura, explores the challenges of current immunotherapy approaches for cancer and where opportunity lies. Immunotherapy has transformed modern oncology. Immune checkpoint inhibitors like pembrolizumab and nivolumab revolutionised melanoma treatment by enhancing immune responses; ensuring it could become a manageable disease – with improved… Read More

#Cancer Research #Exclusive Content

CAR-T therapy
#CAR-T #Cell manufacturing #Cell therapy #Oncology

Bringing CAR-T cell production closer to patients

Dr Liping Yu, Vice President of Applications at Applied Cells, looks at barriers to access for CAR-T cell therapies. CAR-T cell therapies are increasingly being used to treat life-threatening conditions when other treatments have failed, particularly in oncology. Autologous CAR-T cancer therapies involve isolating T cells from a patient’s blood,… Read More

#Cancer Research #Exclusive Content

CRISPR Cas9
#Brain cancer #CRISPR #CRISPR screening #Oncology #The Institute of Cancer Research

CRISPR reveals new therapeutic target for glioblastoma

Scientists have shown for the first time that some of the most persistent cancer cells in glioblastoma rely on transforming growth factor beta-activated kinase 1 (TAK1) for survival and that inhibiting this enzyme leads to the death of the cells.  Furthermore, they have demonstrated that it is… Read More

#Cancer Research #News #Trending News

FDA
#Boehringer Ingelheim #FDA #Non-small cell lung cancer (NSCLC) #Oncology

Targeted medicine for NSCLC receives FDA Priority Review

The US Food and Drug Administration (FDA) has granted Priority Review to Boehringer Ingelheim’s new drug application for zongertinib for unresectable or metastatic non-small cell lung cancer (NSCLC).  It is indicated for adult patients whose tumours have HER2 (ERBB2) mutations and who have received prior systemic therapy. … Read More

#News #Regulatory

#Antibodies #Bispecific Antibodies #Interview #Oncology #Therapeutic Antibodies

Dual-targeted antibody innovations for cancer treatment

David Epstein, Chair & Chief Executive Officer of Ottimo Pharma, speaks to Megan Thomas about innovation in therapeutic antibody development, in the context of the company’s accelerated development of a novel PD1/VEGFR2 bifunctional antibody planned to enter the clinic in 2025, designed as a dual-pathway, single agent, IgG therapy targeting… Read More

#Cancer Research #Exclusive Content

Myeloma cells
#Genetics #Myeloma #Oncology #Personalised medicine #The Institute of Cancer Research

Personalised treatment needed for high-risk myeloma, say scientists

Offering genetic testing to patients with myeloma would help doctors spot those with the most aggressive forms of the disease so that their cancer can be targeted more effectively, say scientists.  With effective treatment, more than half of myeloma patients will survive their disease for five years… Read More

#Cancer Research #Editor's Choice #News

#Acute inflammatory conditions #Fibrosis #Fibrotic disease #GPCRs #Oncology

Is GPR68 a potential master switch for fibrotic and inflammatory diseases?

Simona E Carbone, Michelle P Papadimitriou and Darren J Kelly, discuss why GPR68 has been considered an attractive target for cancer therapy – albeit difficult to drug – and highlight its exciting potential in the development of drugs to treat a range of inflammatory and fibrotic diseases. GPR68, or OGR1,… Read More

#Exclusive Content

The extracellular matrix
#Barts Institute #Oncology #The Institute of Cancer Research #Tumour microenvironment (TME)

Cancer breakthrough could stop tumours before they metastasise

Scientists have discovered a new way to predict which tumours will become aggressive before they metastasise and spread around the body.  The research, published in Nature Communications, reveals how cancer cells are altered by their surroundings, enabling them to change their… Read More

#Cancer Research #News #Trending News

Melanoma or skin cancer
#Immunotherapy #Oncology #Skin cancer #University of Queensland

Cancer immunotherapy reduces skin cancers by 65%

University of Queensland researchers have discovered that immunotherapy, when used to treat people with advanced cancers, also helps reduce sunspots and skin cancers by at least 65%.  Over 12 months, researchers monitored 23 patients receiving immunotherapy for unrelated cancers and found the treatment also targeted cancerous and… Read More

#Cancer Research #News

Scientist using a laptop
#Cancer Research Horizons #Laboratory data #Lifebit #Oncology

Partnership will open access to millions of cancer datasets

Cancer Research Horizons has joined Lifebit’s Federated Data Network to help maximise the impact of data generated through Cancer Research UK-funded research.   This federated network uses Lifebit’s Platform to ensure secure access to standardised datasets of millions of cancer patients from multiple international institutions for use in… Read More

#Cancer Research #News

Neurons
#Lung cancer #Oncology #Small cell lung cancer #The Francis Crick Institute

Lung cancer cells build their own electrical network 

Researchers from the Francis Crick Institute have found that aggressive lung cancer cells can develop their own electric network, like that seen in the nervous system.  This unique property could make them less dependent on the environment surrounding the tumour and even spread more easily, say the… Read More

#Cancer Research #News #Trending News

Medical professional examining mammogram
#Breast cancer #Cancer therapeutics #Drug repurposing #ETH Zurich #Oncology

Digoxin prevents breast cancer metastases in a new study

The active ingredient digoxin, a substance found in foxglove, reduces the number of cells in clusters of breast cancer cells circulating in the blood, new research has found.  These clusters are responsible for the formation of metastases in other organs. The smaller the clusters, the fewer metastases… Read More

#Cancer Research #Editor's Choice #News

Scotland flag
#Oncology #Phase III trial #Regeneron Pharmaceuticals #Scottish Medicines Consortium (SMC)

Scotland approval for cervical cancer therapy

The Scottish Medicines Consortium (SMC) has accepted Libtayo (cemiplimab) for use on the National Health Service (NHS) as a second-line monotherapy for adults with recurrent or metastatic cervical cancer.  It is approved in patients who have disease progression on or after platinum-based chemotherapy, irrespective of PD-L1 expression… Read More

#News #Regulatory

Cancer cell
#CAR-T #Cell therapy #Haematology #Interview #March Biosciences #Oncology

Pushing past the limitations of CAR-T therapies

DDW Editor Reece Armstrong speaks to Sarah Hein, CEO and Co-founder of March Biosciences, about the company’s recent fundraising efforts and its development of CAR-T therapies addressing challenging blood cancers. RA: What are the limitations of current standard-of-care therapies for blood cancers? SH: There are many treatment options for the… Read More

#Exclusive Content

#Cancer therapeutics #Cancer vaccine #CAR-T #Oncology #Radiopharmaceuticals

New DDW Highlights episode: 10 February 2025

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. Following World Cancer Day on 4 February, the news round-up this week focuses on… Read More

#News